Jim Tananbaum

606 posts

Jim Tananbaum banner
Jim Tananbaum

Jim Tananbaum

@JTananbaum

Founder and CEO of @foresitecapital, healthcare venture capital firm.

San Francisco, CA Katılım Kasım 2011
691 Takip Edilen1.2K Takipçiler
Jim Tananbaum
Jim Tananbaum@JTananbaum·
A new cohort of #VCUniversity starts tomorrow through @VCForward, with this amazing group of scholarship recipients in the life sciences track who will be reshaping our industry in years to come. My firm @ForesiteCapital is proud to continue our support of this program.
Venture Forward@VCForward

#VCUniversity Cohort 13 kicks off tomorrow! 🎉 We’re proud to have awarded full scholarships to the course for 40 new and aspiring VCs. Get to know them. 👉

English
1
0
12
852
Jim Tananbaum
Jim Tananbaum@JTananbaum·
I'm thrilled to have joined the @LACMA board to help foster appreciation for culture and creativity in Los Angeles and beyond. Read my thoughts here: @Jim-Tananbaum/on-joining-the-los-angeles-museum-of-modern-art-board-227907b29db4" target="_blank" rel="nofollow noopener">medium.com/@Jim-Tananbaum…
English
1
0
9
1.2K
Jim Tananbaum
Jim Tananbaum@JTananbaum·
Congratulations to the team at @evonetix on this new funding round! We were excited to lead this investment to accelerate the company's commercial strategy and make gene synthesis more accessible.
English
0
0
6
755
Jim Tananbaum
Jim Tananbaum@JTananbaum·
It was an honor to welcome attendees on Saturday at Yale's for Humanity Illuminated event at the Yerba Buena Center. So proud to partner with this team. The @Yale community is incredibly special, and it was an inspirational day.
Jim Tananbaum tweet media
English
0
1
6
0
Jim Tananbaum
Jim Tananbaum@JTananbaum·
I'm excited to support the team at @ElemBio as they unveil their benchtop sequencer AVITI. I believe sequencing will touch all our lives. To enable it, we need high quality, inexpensive sequencing.
Element Biosciences@ElemBio

Hear @JTananbaum Element board member & Founder/CEO of @ForesiteCapital describe how AVITI enables a major shift in the sequencing market. Register for our 3/14 virtual launch event to learn more: bit.ly/3pd3Gkl #AviditySequencing #AVITI #NGS #Biotech #venturecapital

English
0
6
10
0
Jim Tananbaum
Jim Tananbaum@JTananbaum·
Welcoming ImmPACT Bio to our portfolio! Early clinical data is very promising in our view. We believe the efficacy & safety profile of the lead program will help expand access of CAR-T cell therapy to patients who have exhausted other options. Excited to work with this team!
Endpoints News@endpts

ImmPACT Bio unveiled a $111 million Series B round early Thursday morning, along with a C-suite shakeup and a first glimpse at some Phase I data. endpts.com/next-gen-car-t…

English
1
0
3
0